EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

From Gene Editing to Immunotherapy: The Role of CRISPR-Cas9 in Breast Cancer

Shrestha Pal, Semanti Ghosh

Journal of Research in Allied Life Sciences · 12.01.2026 · 2 (1) · 1-8

DOI: 10.65525/jrals.v2i1.17 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Research in Allied Life Sciences, online erschienen am 12.01.2026. Verfasst von Shrestha Pal und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains one of the leading causes of cancer-related mortality among women worldwide with therapeutic resistance and tumour heterogeneity posing major challenges to conventional treatment strategies. Clinical evidence indicates that drug resistance is a great obstacle in breast cancer therapy. Multiple mechanisms contribute to the development of drug resistance, but the underlying cause is usually a shift in the genetic composition of tumour cells. Constant effort is being made to introduce novel therapies with minimal toxicity. The advent of CRISPR-Cas9 genome editing has revolutionized cancer biology by enabling precise and efficient manipulation of genetic material. In breast cancer research, CRISPR-Cas9 has been employed to knockout oncogenes such as HER2 and MYC, repair or model BRCA1/2 mutations, and investigate mechanisms of drug resistance. Furthermore, CRISPR-based approaches are being explored in diagnostics, such as the rapid detection of BRCA mutations, and in immunotherapy, where gene editing enhances the efficacy of immune checkpoint blockade and adoptive cell transfer therapies. Recent studies have also demonstrated the potential of CRISPR-Cas9 delivered via nanoparticles to reprogram tumour microenvironments and improve anti-tumour immunity. However, significant challenges remain, including off-target effects, safe and targeted delivery to tumour tissues, and ethical considerations, particularly concerning germline editing. Despite these limitations, CRISPR-Cas9 holds immense promise in advancing personalized and precision medicine for breast cancer, offering new avenues for effective therapies and early detection. This review current applications, emerging strategies, and future directions of CRISPR-Cas9 in breast cancer research and therapy.

Zitieren

APA

Pal, S., & Ghosh, S. (2026). From Gene Editing to Immunotherapy: The Role of CRISPR-Cas9 in Breast Cancer. Journal of Research in Allied Life Sciences, 2(1), 1-8. https://doi.org/10.65525/jrals.v2i1.17

Vancouver

Pal S, Ghosh S. From Gene Editing to Immunotherapy: The Role of CRISPR-Cas9 in Breast Cancer. Journal of Research in Allied Life Sciences. 2026;2(1):1-8. doi:10.65525/jrals.v2i1.17

BibTeX
@article{Pal2026,
  author = {Pal, Shrestha and Ghosh, Semanti},
  title = {From Gene Editing to Immunotherapy: The Role of CRISPR-Cas9 in Breast Cancer},
  journal = {Journal of Research in Allied Life Sciences},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {1--8},
  doi = {10.65525/jrals.v2i1.17}
}
Kostenlos starten →